Investigational drug · Phase 2
intraocular implant releasing timolol
Also called: TimoD implant
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Glaucoma, Ocular Hypertension.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "intraocular implant releasing timolol"
First trial start
2025
Jun 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "intraocular implant releasing timolol", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glaucoma
- Ocular Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Glaucoma · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "intraocular implant releasing timolol" as an intervention, largest first.
EyeD PharmaIndustry
NCT07036510 · 42 participants (planned) · Start Jun 12, 2025 · Primary completion Jan 2027
Drug: TimoD implant; Timolol eye drops 0.5% · For: Glaucoma; Ocular Hypertension
Sites: Panama City, Panama
EyeD PharmaIndustry
NCT06321562 · 1 participants · Start Mar 1, 2023 · Primary completion Jun 26, 2025
Drug: TimoD implant · For: Primary Open-angle Glaucoma
Sites: Düsseldorf, Germany; Heidelberg, Germany; Magdeburg, Germany · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Glaucoma
- Bimatoprost Implant SystemPhase 33 trials
SpyGlass Pharma, Inc. · Cataract, Glaucoma, Ocular Hypertension
- Timolol eye drops 0.5%Phase 33 trials
Glaukos Corporation · Glaucoma, Ocular Hypertension
- Gen 2 Travoprost Intracameral ImplantGen 2 Travoprost Intraocular ImplantPhase 32 trials
Glaukos Corporation · Glaucoma
- Inactive controlQLS-111 vehiclePhase 32 trials
Can-Fite BioPharma · Hepatocellular Carcinoma, Cirrhosis, Open-angle Glaucoma (OAG)
- QLS-111Phase 23 trials
Qlaris Bio, Inc. · Normal Tension Glaucoma (NTG), Glaucoma, Open-angle Glaucoma (OAG)
- BL1107Phase 22 trials
Bausch & Lomb Incorporated · Dry Eye Disease, Glaucoma
- ASP2767Phase 21 trial
Astellas · Glaucoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.